LGALS3 and non-small cell lung carcinoma: Thus, in the present study, we investigated the regulatory effect of Gal‐3 on PD‐L1 expression and the potential pathways through which it functions in the NSCLC cell line A549, and we also examined the effects of combined treatment using a Gal‐3 inhibitor with PD‐L1 blockade in vitro and in vivo.